B. coagulans SNZ 1969 Raised NK Cell Activity 44% in Double-Blind RCT

Natural killer cells are the body's first cytotoxic line — innate lymphocytes that detect and destroy virus-infected and aberrant cells without prior sensitization. In healthy older adults, their functional capacity typically declines with age, a process well characterized in the immunosenescence literature. In this 12-week double-blind randomized controlled trial, adults aged 60–65 who received Bacillus coagulans SNZ 1969® at 2 billion colony-forming units daily saw NK cell cytotoxic activity increase by 44.59%. The placebo group recorded a 2.52% change over the same period (p = 0.0002). In an age group where immune surveillance is already under pressure from natural aging, a 42-percentage-point gap between groups is the kind of result that demands an explanation of mechanism — not just a headline.

This trial, published in Cureus in 2025, enrolled 60 adults and measured NK cell cytotoxicity alongside immunoglobulin A levels in both serum and saliva — two distinct arms of the immune system that rarely appear together in a single fermented food trial. The serum IgA result (+25.0% vs +2.3%, p = 0.0016) and the salivary IgA result (+27.7% vs +0.6%, p = 0.0002) were both highly significant. Taken together, the three primary outcomes provide a simultaneous window into innate cytotoxic capacity and mucosal secretory defense — the two systems that intercept most pathogen encounters before adaptive immunity is ever called upon.

Key Findings

NK = natural killer cell. IgA = immunoglobulin A. GI infection incidence and illness day totals are descriptive secondary endpoints; the trial was not powered to achieve statistical significance on these measures. Both primary (NK) and secondary (serum IgA, salivary IgA) outcomes reached significance.

Mechanism: How B. coagulans Acts on Innate Immune Surveillance

TLR2 Signaling and NK Cell Activation

Bacillus coagulans forms endospores — dormant, metabolically inert structures enclosed in a protein coat — that survive gastric acid transit intact and germinate in the small intestine. The surface proteins and peptidoglycan fragments released during germination are recognized by toll-like receptor 2 (TLR2), a pattern recognition receptor expressed on intestinal epithelial cells, macrophages, dendritic cells, and monocytes. TLR2 activation initiates an intracellular signaling cascade through the adaptor protein MyD88 and the transcription factor NF-κB, driving production of pro-inflammatory cytokines including interleukin-12 (IL-12) and IL-18. IL-12 is a potent activator of natural killer cells: it drives NK cell proliferation, upregulates activating surface receptors including NKG2D and NKp44, and amplifies cytotoxic granule release — specifically perforin and granzyme B, the proteins NK cells use to lyse target cells. The result is a sharper, faster cytotoxic response to virus-infected or aberrant cells. This is not generalized immune stimulation. It is a specific, receptor-mediated chain of molecular events that begins with a germinating spore coat recognized at the epithelial surface and ends with an NK cell functionally better equipped to identify and eliminate its target.

GALT-Driven IgA Upregulation

The gut-associated lymphoid tissue — comprising Peyer's patches, isolated lymphoid follicles, and mesenteric lymph nodes — contains the largest concentration of IgA-producing plasma cells in the body. Dendritic cells in the lamina propria sample luminal microbial signals and, when stimulated via pattern recognition including TLR2, migrate to Peyer's patches and present antigen to naïve B cells. Under the influence of T follicular helper cells and cytokines including APRIL and BAFF, these B cells undergo class-switch recombination from IgM to IgA and differentiate into long-lived plasma cells that secrete dimeric IgA. That IgA is transported across the intestinal epithelium via the polymeric immunoglobulin receptor (pIgR) and released into the gut lumen, where it coats and neutralizes pathogens before they can adhere to the epithelium. The salivary IgA signal detected in this trial almost certainly reflects the same systemic GALT activation: IgA-committed plasma cell precursors generated in gut lymphoid tissue migrate via the circulation to distant mucosal sites, including salivary glands, where they differentiate and secrete locally. The concurrent elevation of IgA in both serum and saliva suggests the immune activation initiated in the gut was not locally confined but distributed across the common mucosal immune system — a meaningful distinction for understanding how this effect might generalize to multiple mucosal barriers simultaneously.

Vital Yogurts Connection: Glacier

Glacier contains Bacillus coagulans as its primary live fermented culture. Unlike heat-sensitive Lactobacillus and Bifidobacterium species, B. coagulans forms heat-stable spores that tolerate the temperatures reached during yogurt production — a structural property that distinguishes it in the category of live fermented milks and that has direct practical significance for what arrives in the intestine. The spore structure that makes B. coagulans uniquely survivable through manufacturing is the same structure that initiates TLR2 signaling after germination in the gut. The culture is not degraded in transit. It arrives intact and in the form the immune system recognizes.

This trial used 2 billion CFU daily — a dose at the lower end of clinically studied ranges for this species. Glacier's Valley tier delivers 20B CFU per serving; Reserve delivers 40B CFU; Summit delivers 60B CFU. Whether the larger immune effects observed at higher doses in other contexts scale linearly has not been directly tested against these specific immunological endpoints, but the study establishes that the culture at a fraction of Glacier's serving dose produced statistically significant changes in NK activity and IgA. The question of optimal dose remains open for future research. What this trial establishes is that the culture in Glacier is the culture the research was built around.

Protocol Implications

The trial design was straightforward: 2 billion CFU per day for 12 weeks, daily and consistent, no washout, no interim biomarker assessments. That design tells us what the endpoint looks like after 12 weeks of steady intake, but it does not tell us when the changes began accumulating — whether NK activity diverged from placebo at four weeks or only at ten. What it does establish is that 12 weeks of uninterrupted daily intake is sufficient to produce the measured effects. For practical purposes, a three-month minimum window is the relevant horizon for evaluating whether this culture is doing what the evidence says it can do. The immunological trajectory described here — steady GALT stimulation, consistent TLR2 engagement, progressive IgA class switching and NK priming — is not the product of occasional use. It reflects the kind of sustained microbial exposure that drives durable immune calibration. A daily serving of Glacier for twelve weeks matches exactly the consumption pattern this study was built around, and provides a reasonable and evidence-anchored framework for evaluating response in real-world practice.

Vital Yogurts — Glacier

The culture studied is in Glacier.

Bacillus coagulans SNZ 1969®

This trial found that the specific culture in Glacier raised NK cell cytotoxic activity by 44.59% and elevated both serum and salivary IgA significantly versus placebo over 12 weeks in adults at elevated infection risk. Glacier's heat-stable spore formation is what makes B. coagulans viable through the yogurt-making process and through gastric transit — arriving in the intestine intact and in the form the immune research was built around.

Valley — 20B CFU Reserve — 40B CFU Summit — 60B CFU

Shop Glacier

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet or supplement routine. The studies cited are referenced for informational context; Vital Yogurts makes no therapeutic or disease treatment claims.